Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

• Status: Recruiting
• Trial end date: 2023-10-24

Summary

This is a prospective multicenter single-arm phase II study, and the purpose of this study is to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma. Overall response rate （ORR） after 4 cycles is the primary endpoint.

• Phase: Phase 2

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Collaborators: Beijing Hospital; Beijing Luhe Hospital; Beijing Tongren Hospital; Henan Cancer Hospital; Henan Province Renmin Hospital; Qilu Hospital of Shandong University; Shanxi Province Renmin Hospital; The First Hospital of Chinese Medical University; The First Hospital of Zhengzhou University; The Forth Hospital of Hebei Medical University; The Second Affiliated Hospital of Dalian Medical University